Literature DB >> 15956591

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Margherita Rosati1, Agneta von Gegerfelt, Patricia Roth, Candido Alicea, Antonio Valentin, Marjorie Robert-Guroff, David Venzon, David C Montefiori, Phil Markham, Barbara K Felber, George N Pavlakis.   

Abstract

We have tested the efficacy of DNA immunization as a single vaccination modality for rhesus macaques followed by highly pathogenic SIVmac251 challenge. To further improve immunogenicity of the native proteins, we generated expression vectors producing fusion of the proteins Gag and Env to the secreted chemokine MCP3, targeting the viral proteins to the secretory pathway and to a beta-catenin (CATE) peptide, targeting the viral proteins to the intracellular degradation pathway. Macaques immunized with vectors expressing the MCP3-tagged fusion proteins developed stronger antibody responses. Following mucosal challenge with pathogenic SIVmac251, the vaccinated animals showed a statistically significant decrease in viral load (P = 0.010). Interestingly, macaques immunized with a combination of vectors expressing three forms of antigens (native protein and MCP3 and CATE fusion proteins) showed the strongest decrease in viral load (P = 0.0059). Postchallenge enzyme-linked immunospot values for Gag and Env as well as gag-specific T-helper responses correlated with control of viremia. Our data show that the combinations of DNA vaccines producing native and modified forms of antigens elicit more balanced immune responses able to significantly reduce viremia for a long period (8 months) following pathogenic challenge with SIVmac251.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956591      PMCID: PMC1143718          DOI: 10.1128/JVI.79.13.8480-8492.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  More powerful procedures for multiple significance testing.

Authors:  Y Hochberg; Y Benjamini
Journal:  Stat Med       Date:  1990-07       Impact factor: 2.373

2.  Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration.

Authors:  D H Barouch; S Santra; T D Steenbeke; X X Zheng; H C Perry; M E Davies; D C Freed; A Craiu; T B Strom; J W Shiver; N L Letvin
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

Review 3.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; M A Liu
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

4.  In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen.

Authors:  J J Kim; V Ayyavoo; M L Bagarazzi; M A Chattergoon; K Dang; B Wang; J D Boyer; D B Weiner
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

Review 5.  Genetic immunization: a new era in vaccines and immune therapeutics.

Authors:  M Chattergoon; J Boyer; D B Weiner
Journal:  FASEB J       Date:  1997-08       Impact factor: 5.191

6.  Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation.

Authors:  R Schneider; M Campbell; G Nasioulas; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  beta-catenin is a target for the ubiquitin-proteasome pathway.

Authors:  H Aberle; A Bauer; J Stappert; A Kispert; R Kemler
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

8.  HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha.

Authors:  C Lekutis; J W Shiver; M A Liu; N L Letvin
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

9.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

Authors:  R R MacGregor; J D Boyer; K E Ugen; K E Lacy; S J Gluckman; M L Bagarazzi; M A Chattergoon; Y Baine; T J Higgins; R B Ciccarelli; L R Coney; R S Ginsberg; D B Weiner
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

Authors:  Thorsten U Vogel; Matthew R Reynolds; Deborah H Fuller; Kathy Vielhuber; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; Marta L Marthas; Volker Erfle; Steven M Wolinsky; Chenxi Wang; David B Allison; Erling W Rud; Nancy Wilson; David Montefiori; John D Altman; David I Watkins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  68 in total

1.  Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Authors:  Vainav Patel; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Cristina Bergamaschi; Rashmi Jalah; Candido Alicea; Jacob T Minang; Matthew T Trivett; Claes Ohlen; Jun Zhao; Marjorie Robert-Guroff; Amir S Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.

Authors:  Yongjun Sui; Qing Zhu; Susan Gagnon; Amiran Dzutsev; Masaki Terabe; Monica Vaccari; David Venzon; Dennis Klinman; Warren Strober; Brian Kelsall; Genoveffa Franchini; Igor M Belyakov; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

3.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

5.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

6.  Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Authors:  Donald N Forthal; Gary Landucci; Kelly Stefano Cole; Marta Marthas; Juan C Becerra; Koen Van Rompay
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

8.  Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques.

Authors:  Viraj Kulkarni; Margherita Rosati; Jenifer Bear; Guy R Pilkington; Rashmi Jalah; Cristina Bergamaschi; Ashish K Singh; Candido Alicea; Bhabadeb Chowdhury; Gen-Mu Zhang; Eun-Young Kim; Steven M Wolinsky; Wensheng Huang; Yongjun Guan; Celia LaBranche; David C Montefiori; Kate E Broderick; Niranjan Y Sardesai; Antonio Valentin; Barbara K Felber; George N Pavlakis
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

9.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency.

Authors:  Chih-Ping Mao; Chien-Fu Hung; Tae Heung Kang; Liangmei He; Ya-Chea Tsai; Chao-Yi Wu; T-C Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.